Health Care • Biotechnology: Pharmaceutical Preparations
$0.29 ▲ +0.03
(+11.36%)
MKT CAP: $17.4M • VOL: 1.35M
52W L $0 52W H $1
ROARABLE / RQD
D • 48/100
PIOTROSKI
1 / 9
AEON // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $0 |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$12.8M | $73.0M |
| Operating Margin % | — | — |
| Net Income (GAAP) | -$39.2M | $42.0M |
| EBITDA (Normalized) | -$12.8M | — |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$17.3M | -$20.3M |
| Capital Expenditures (CapEx) | $4.0K | — |
| Free Cash Flow (FCF) | -$17.3M | -$20.3M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | 95.0% |
| Cash & Short-Term Equivalents | $3.0M | $13.0K |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | -$55.0M | -$28.6M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AEON.